The COMPASSION-15 trial demonstrated that chemotherapy plus cadonilimab improved progression-free survival and overall survival in untreated HER2-negative patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma compared to chemotherapy alone [53]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.